TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CEFTAZIDIME IN DEXTROSE CONTAINER

CEFTAZIDIME
Approved 2011-06-13
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2011-06-13
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

B BRAUN
Active Ingredient: CEFTAZIDIME

CEFTAZIDIME IN DEXTROSE CONTAINER Approval History

Loading approval history...

What CEFTAZIDIME IN DEXTROSE CONTAINER Treats

1 FDA approvals

Originally approved for its first indication in 2011 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFTAZIDIME IN DEXTROSE CONTAINER FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA050823 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.